Our diverse programs, flexible investment strategies, and specialized teams allow us to identify and pursue innovative investment opportunities successfully.
We are focused on defensive equity exposure through a concentrated portfolio of attractively valued securities. These comprise high quality developed market equities, supported by strong, balanced sheets and with limited risk of permanent capital impairment.
Our approach involves a focus on consistent returns over the long run by gaining exposure to a broadly diversified mix of asset classes.
We seek to realize attractive risk-adjusted returns in global credit markets, based on disciplined fundamental bottom-up research. To help achieve this, we partner with world-class asset managers and also look at private credit opportunities, where our flexibility in structuring capital solutions to third parties provides added value to our partners.
We deploy capital, resources and expertise to support innovative life science companies as they address unmet medical needs and improve the quality of life of patients around the world. In addition to pharmaceutical royalties, the group’s mandate includes investments across the capital structure in commercial-stage biopharma and medical device companies.
We invest alongside like-minded partners, such as private equity sponsors, strategic operators, and issuers, who have reliable track records, and in transactions that provide us with alignment, down-side protection, and management capabilities.